ArticleEuropean journal of pediatrics2025
RSV bronchiolitis: a disease only for those who do not receive prophylaxis.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants.Pediatric pulmonology · 2026Article
- Early and high Influenza A circulation alongside reduced Respiratory Syncytial Virus prevalence during autumn 2025 in paediatric patients attending emergency department.Italian journal of pediatrics · 2026Article
- Real-World Effectiveness of Universal Nirsevimab on Bronchiolitis Incidence: A Regional Hub-Spoke Surveillance Analysis in Liguria, Italy.Pediatric pulmonology · 2026Article
- Global trends and advances in pediatric bronchiolitis treatment in the last two decades: a bibliometric analysis.Journal of thoracic disease · 2026Article
- Impact of Nirsevimab on bronchiolities in pediatric primary care in Lazio Region: an observational study.Italian journal of pediatrics · 2026Observational
- Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study.Italian journal of pediatrics · 2026Observational
- Insights into epidemiological and clinical burden of bronchiolitis among hospitalized children: a call for preventive interventions.Frontiers in pediatrics · 2026Article
- Diagnosis, management, and prevention of bronchiolitis in primary care: a survey of Italian family paediatricians.Italian journal of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiolitis is a leading cause of hospitalization in infants, with RSV being the primary pathogen. In 2023, nirsevimab was approved for universal prophylaxis, demonstrating high effectiveness in reducing RSV-related hospitalizations. In Italy, nirsevimab was introduced in the vaccination schedule only during the current 2024-2025 epidemic season, with significant regional differences. In our region, Lazio, nirsevimab was introduced in late November 2024, leading only to a 43% overall reduction in RSV bronchiolitis hospitalizations compared to the previous season. The highest impact was observed in newborns immunized at birth (- 82.7%), while the catch-up group showed lower-than-expected benefits (- 29%). Immunized infants had significantly lower oxygen requirements (42.9% vs. 82.4% in non-immunized) and resulted to be approximately seven times more likely not to require oxygen compared to non-immunized patients.
conclusionUniversal infant immunization against RSV marks a significant breakthrough in the natural history of bronchiolitis, and early and widespread nirsevimab administration appears to be crucial in minimizing RSV's hospitalizations. WHAT IS KNOWN: • Nirsevimab was approved in 2023 for the universal prophylaxis against RSV bronchiolitis. • Nirsevimab was was introduced in the Italian vaccination schedule only during the current 2024-2025 epidemic season, with significant regional differences. WHAT IS NEW: • In Lazio, Italy, the delayed introduction of nirsevimab in November 2024 and the reduced vaccination coverage of the catch-up group resulted in a lower-than-expected reduction in RSV bronchiolitis hospitalizations. • Early and widespread administration of nirsevimab is crucial to maximizing its benefits and reducing severe RSV cases.
Indexed as
Identifiers
40555916What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.